Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres

Cancer Immunology Immunotherapy

Volumn 47, Issue 1, 1998, Pages 13-20

  Ma, Jie ^a   Samuel, John ^b   Kwon, Glen S ^b,c   Noujaim, Antoine A ^a   Madiyalakan, Ragupathy ^a  

^a AltaRex Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Anti idiotypic antibody; Cancer vaccine; Microspheres; Poly(DL lactic co glycolic acid)

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; MICROSPHERE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; BIODEGRADATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; ENCAPSULATION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; BIOCOMPATIBLE MATERIALS; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNITY, CELLULAR; LACTIC ACID; MICE; MICE, INBRED BALB C; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; T-LYMPHOCYTES;

EID: 0031713603     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050499     Document Type: Article

References (44)

1. Aguado MT (1993) Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 11:596
2. Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR Jr, Knapp RC (1984) Monitoring human ovarian carcinoma with a combination of CA125, CA19-9, and carcinoembryonic antigen. Am J Obstet Gynccol. 149:553
3. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnesrstag B, Sykes T, Boniface G, Hor G (1993) Clinical course of ovarian cancer patients under repeated stimulation of HAMA using mAb OC125 and B43.13. Hybridoma 12:583
4. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, Hor G (1994) Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 73:1121
5. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Kholer H (1990) Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 145:2758
6. Capstidk V, Maclean GD, Suresh MR, Bodnar D, Shepert L, Longenecker BM, Krantz M (1991) Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biomarkers 6:129
7. Chattopadhyay P, Starkey J, Morrow MJW, Raychoudhuri S (1992) Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc Natl Acad Sci USA 89:2684
8. Chen ZJ, Yang H, Ferrone S (1991) Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts. J Immunol 147:1082
9. Cohen S, Alonso MJ, Langer R (1994) Novel approaches to controlled-release antigen delivery. Int J Technol Assess Health Cure 10:121
10. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM (1991) Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59:2978
11. Eldridge JH, Staas JK, Chen D, Marx PA, Tice TR, Gilley RM (1993) New advances in vaccine delivery system. Semin Heinatol 30 [Suppl 4]:16
12. Fagerberg J, Frodin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H (1994) Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (abl). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother 38:149
13. Fagerberg J, Hjelm AL, Ragnhammar P, Frodin J-E, Wigzell H, Mellstedt H (1995) Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 55:1824
14. Fagerberg J, Ragnhammar P, Liljeflrs M, Hjelm AL, Mellstedt H (1996) Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 42:81
15. Faulmann EL, Otten RA, Barrett DJ, Boyle MD (1989) Immunological applications of type III Fe binding proteins. Comparison of different sources of protein G. J Immunol Methods 123:269
16. Ferrone S (1993) Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb. Ann NY Acad Sci. 690:214
17. Germann T, Bongartz, M, Dlugonska H, Schmitt E, Kolbe L, Kolsch E, Podlaski FJ, Gately MK, Rude E (1995) Interleukin 12 profoundly upregulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 25:823
18. Guery JC, Galbiati F, Smiroklo S, Adorini L (1996) Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta (2)-microglobulin-deficient BALB/c mice. J Exp Med 183:485
19. Gustafson GL, Rhodes MJ (1994) Effects of tumor necrosis factor and dexamethasone on the regulation of interferon-gamma induction by monophosphoryl lipid A. J Immunother 15:129
20. Hamby CV, Liao SK, Kanamaru T, Ferrone S (1987) Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res 47:5284
21. Hathcock K (1994) Protocols in immunology. Wiley, New York, p 3.2.1
22. Herlyn D, Ross AH, Iliopulos D, Koprowski H (1987) Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody CO17-1A. Eur J Immunol 17:1649
23. Herlyn D, Harris D, Zaloudik J, Sperlagh M, Maruyama H, Jacob L, Kieny M-P, Scheck S, Somasundaram R, Hart E, Ertl H, Mastrangelo M (1994) Immunomodulatory activity of monoclonal anti-idiolypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J Immunother Emphasis Tumor Immunol 15:303
24. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373
25. Jerne NK, Roland J, Cazenave PA (1982) Recurrent idiotopes and internal images. EMBO J 1:243
26. 123I-gastrin by plasma membranes from homogenized rat gastric mucosa. Scand J Gastroenterol 21:547
27. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF (1984) Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 8:216
28. Krantz MJ, Maclean G, Longenecker BM, Suresh MR (1988) A radioimmunoassay for CA125 employing two new monoclonal antibodies. J Cell Biochem (Suppl 12) E: 139
29. Losman MJ, Hansen HJ, Sharkey RM, Goldenberg DM, Monestier M (1991) Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen. Proc Natl Acad. Sci. USA 88:3421
30. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hor G, Noujaim AA (1995) Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 14:199
31. Madiyalakan R, Yang R, Schutes B, Baum RP, Noujaim AA (1997) OVAREX mAb-B43.13: IFN-γ could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Hybridoma 16:41
32. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T (1988) A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic/glycolic) acid. Chem Pharm Bull 36:1095
33. O'Hagan DT, Jeffery H, Maloy KJ, Mowat AM, Rahman D, Challacombe SJ (1995) Biodegradable microparticles as oral vaccines. Adv Exp Med Biol 37IB:1463
34. Pan Y, Yuhasz SC, Amzel EM (1995) Anti-idiotypic antibodies: biological function and structural studies. FASEB J 9:43
35. Poljak RJ (1994) An idiotope-anti-idiotope complex and the structural basis of molecular mimicking. Proc Natl Acad Sci USA 91:1599
36. Reinsberg J (1993) Idiotypic cascades after mAb OC125 application. Hybridoma 12:577
37. Reinsberg J, Heydweiller A, Wagner U, Pfeil K, Oehr P, Krebs D (1990) Evidence for interaction of human anti-idiotypic antibodies with CA125 determination in a patient after radioimmunodetection. Clin Chem 36:164
38. Salacinski PRP, McLean C, Sykes JEC, Clement-Jones VV, Lowry PJ (1981) Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetra-chloro-3α, 6α-dipenyl glycoluril (IODO-GEN). Anal Biochem 117:136
39. Scheicher C, Mehlig M, Dienes HP, Reske K (1995) Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-I alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol 25:1566
40. Schlebsch H, Wagner U, Grunn U, Schultes B (1995) A monoclonal antiidiotypic antibody ACA125 mimicking the tumor-associated antigen CA125 for immunotherapy of ovarian cancer. Hybridoma 14:167
41. Schmolling J, Reinsberg J, Wagner U, Krebs D (1997) Anti-TAG-72 antibody B72.3 immunological and clinical effects in ovarian carcinoma. Hybridoma 16:53
42. Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Kane M, Mastrangelo M, Herlyn D (1995) Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 155:3253
43. Wagner U (1993) Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma 12:521
44. Whittum-Hudson JA, An L, Saltzman WM, Prendergast RA, MacDonald AB (1996) Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat Med 2:1116